Mark Bodmer, Ph.D. has served as Chief Scientific Officer and President of Research and Development since 2016. Prior to joining Evelo, Mark was Vice President of New Medicines Therapeutics at UCB S.A. Mark also served as Senior Vice President of Neuroinflammation at GSK, as well as a member of the Board of Directors of BioIndustry Association. Mark received his Ph.D. from Cambridge University.
Mark Bodmer, Ph.D.
President of R&D, Chief Scientific Officer